Revision 7212879 of "Alvotech" on simplewiki

{{Infobox company
| name = Alvotech
| industry = [[​​​Biopharmaceuticals]]
| founders = Chris Erhardt & Mylene Besancon
| founded = 2013<ref>{{cite web |title=Alvotech and STADA Agree on Strategic Biosimilar Partnership |url=https://www.bloomberg.com/press-releases/2019-11-06/alvotech-and-stada-agree-on-strategic-biosimilar-partnership |website=Bloomberg.com |language=en |date=6 November 2019}}</ref>
| key_people = ​​​Robert Wessman, Chairman<br/>Mark Levick, CEO
| location_country = [[Reykjavík]], Iceland<ref>{{cite web |title=Alvotech and CCHN partner on biosimilars in China |url=https://www.thepharmaletter.com/article/alvotech-and-cchn-partner-on-biosimilars-in-china |website=www.thepharmaletter.com}}</ref>
| num_employees = 220
| homepage = [https://www.alvotech.com/ www.alvotech.com]
}}
 
'''Alvotech''' is a [[privately-owned]], multinational [[biopharmaceutical]] company that develops and manufactures [[biosimilar]] products for the [[treatment of cancer]] and [[autoimmune]] and [[inflammatory diseases]]. The company was founded in 2013 by chief executive and chairman of sister company Alvogen, Robert Wessman.<ref>{{cite web |title=Stocks |url=https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=257527922 |website=Bloomberg.com |language=en}}</ref><ref>{{cite web |title=Alvotech, DKSH Partner To Bring Biosimilar To Asia |url=https://www.contractpharma.com/contents/view_breaking-news/2020-03-26/alvotech-dksh-partner-to-bring-biosimilar-to-asia/ |website=Contract Pharma}}</ref>
 
The company’s manufacturing facility opened in Reykjavík, Iceland in 2016, and is dedicated to the production of biosimilars of monoclonal antibodies.<ref>{{cite web |title=Single-Use Bioprocessing - US |url=http://www.finesse.com/media/252866/Fjalar-Kristjansson-Alvotech.pdf |website=www.thermofisher.com |language=en}}</ref><ref>{{cite web |title=Alvotech’s Biosimilars Manufacturing Facility, Reykjavik |url=http://www.pharmaceutical-technology.com/projects/alvotechs-biosimilars-manufacturing-facility-reykjavik/ |website=Pharmaceutical Technology}}</ref>
 
Alvotech’s headquarters are in [[Reykjavík, Iceland]], with additional research, development and regulatory centres across in Switzerland, Germany and the U.S. The company’s international team includes around 500 scientists and professionals.<ref>{{cite web |title=Our locations - Alvotech |url=http://www.alvotech.com/research-and-development/locations |archive-url=http://web.archive.org/web/20161024194826/http://www.alvotech.com/research-and-development/locations |archive-date=24 October 2016}}</ref><ref>{{cite web |title=Teva enters biosimilar commercialisation partnership with Alvotech |url=https://www.pharmaceutical-technology.com/news/teva-alvotech-biosimilar-deal/ |website=www.pharmaceutical-technology.com}}</ref>
 
==History==
Alvotech was founded in 2013 by the chairman and chief executive of Alvogen, Robert Wessman.<ref>{{cite web |title=ABDİ İBRAHİM AND ALVOTECH ENTER STRATEGIC PARTNERSHIP IN BIOTECHNOLOGY |url=https://www.cphi-online.com/abdi-ibrahim-and-alvotech-enter-strategic-news085050.html |website=www.cphi-online.com}}</ref> Shortly after its launch, the company announced its strategy to invest in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.<ref>{{cite web |title=Growth story - Alvotech |url=http://www.alvotech.com/company/growth-story |archive-url=http://web.archive.org/web/20160612025127/http://www.alvotech.com/company/growth-story |archive-date=12 June 2016}}</ref><ref>{{cite web |title=Alvotech, JAMP Pharma Ink Biosim Deal |url=https://www.contractpharma.com/contents/view_breaking-news/2020-01-15/alvotech-jamp-pharma-ink-biosim-deal/ |website=Contract Pharma}}</ref>
 
In 2014, the development of new products was initiated, further enhancing Alvotech’s pipeline of biosimilar candidates. The company entered a partnership with Finesse Solutions, which provided Alvotech with scalable, flexible and cost-effective laboratory and manufacturing technology via its turnkey SmartFactory® GMP manufacturing platform suite.<ref>{{cite web |title=Single-Use Bioprocessing - US |url=http://www.finesse.com/company/press-room/news/2014/03/alvotech-and-finesse-announce-exciting-bio-manufacturing-collaboration/ |website=www.thermofisher.com |language=en}}</ref>
 
In 2016, Alvotech acquired German biopharmaceutical development company Baliopharm.<ref>{{cite web |title=Alvotech acquires Baliopharm |url=https://www.manufacturingchemist.com/news/article_page/Alvotech_acquires_Baliopharm/118291 |website=www.manufacturingchemist.com}}</ref> The company opened its research and development centre in the Science Park of the University of Iceland, Reykjavík, at the start of June that year.<ref>{{cite web |title=Alvotech grand opening in Reykjavik |url=http://www.invest.is/press--media/news/invest/alvotech-grand-opening-in-reykjavik-today/234 |website=www.invest.is}}</ref><ref>{{cite web |title=R&D - Alvotech |url=http://www.alvotech.com/research-and-development |archive-url=http://web.archive.org/web/20161024194549/http://www.alvotech.com/research-and-development |archive-date=24 October 2016}}</ref>

==References==
{{Reflist}}